Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
Ya-Qin Zheng, Rui Huang, Wen-Lu Zou, Chao Liu, H. Niu, J. Yue
{"title":"Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer","authors":"Ya-Qin Zheng, Rui Huang, Wen-Lu Zou, Chao Liu, H. Niu, J. Yue","doi":"10.1002/pro6.1156","DOIUrl":null,"url":null,"abstract":"The prognosis for unresectable locally advanced pancreatic cancer (LAPC) is still poor, and the best therapeutic option is still unknown. The common treatments for LAPC, concurrent chemoradiotherapy (CCRT), 125I seed implantation combined with chemotherapy (125IC), and chemotherapy alone (CA), were studied. In addition, we looked into the impact of radiation dose on the survival of patients receiving chemoradiotherapy.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pro6.1156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The prognosis for unresectable locally advanced pancreatic cancer (LAPC) is still poor, and the best therapeutic option is still unknown. The common treatments for LAPC, concurrent chemoradiotherapy (CCRT), 125I seed implantation combined with chemotherapy (125IC), and chemotherapy alone (CA), were studied. In addition, we looked into the impact of radiation dose on the survival of patients receiving chemoradiotherapy.